| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2153763 | Nuclear Medicine and Biology | 2013 | 5 Pages |
Introduction4-Borono-2-18 F-fluoro-phenylalanine (18 F-FBPA) has been used to anticipate the therapeutic effects of boron neutron capture therapy (BNCT) with 4-borono-L-phenylalanine (BPA). Similarly, L-[methyl-11C]-methionine (11C-MET), the most popular amino acid PET tracer, is a possible candidate for this purpose. We investigated the transport mechanism of 18 F-FBPA and compared it with that of 14C-MET in human glioblastoma cell lines.MethodsUptake of 18 F-FBPA and 14C-MET was examined in A172, T98G, and U-87MG cells using 2-aminobicyclo-(2.2.1)-heptane-2-carboxylic acid (a system L-specific substrate), 2-(methylamino)-isobutyric acid (a system A-specific substrate), and BPA. Gene expression was analyzed by quantitative real time polymerase chain reaction.ResultsSystem L was mainly involved in the uptake of 18 F-FBPA (74.5%–81.1% of total uptake) and 14C-MET (48.3%–59.4%). System A and ASC also contributed to the uptake of 14C-MET. Inhibition experiments revealed that BPA significantly decreased the uptake of 18 F-FBPA, whereas 31%–42% of total 14C-MET uptake was transported by BPA non-sensitive transporters. In addition, 18 F-FBPA uptake correlated with LAT1 and total LAT expressions.ConclusionThis study demonstrated that 18 F-FBPA was predominantly transported by system L in human glioblastoma cells compared to 14C-MET. Although further studies are needed to elucidate the correlation between 18 F-FBPA uptake and BPA content in tumor tissues, 18 F-FBPA is suitable for the selection of patients who benefit from BNCT with BPA.
